MCID: GST012
MIFTS: 37

Gastroesophageal Junction Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases, Cardiovascular diseases

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

Aliases & Descriptions for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma 12 14
Adenocarcinoma of the Gastroesophageal Junction 69
Adenocarcinoma of Cardioesophageal Junction 12
Adenocarcinoma of Gastroesophageal Junction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4944
NCIt 47 C9296
UMLS 69 C1332166

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to adenocarcinoma and esophagitis, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are PAK Pathway and Tyrosine Kinases / Adaptors. The drugs Herceptin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotype is skeleton.

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
id Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.6
2 esophagitis 10.1
3 multinodular goiter 9.9 ERBB2 KDR
4 proctitis 9.9 ERBB2 SNAI1
5 diphallia 9.9 ERBB2 IL1B
6 mikulicz disease 9.9 ERBB2 IL1B
7 metagonimiasis 9.9 ERBB2 KDR
8 histoplasmosis retinitis 9.8 IL1B SNAI1
9 h. pylori infection 9.8
10 meningitis 9.8
11 spindle cell hemangioma 9.3 ERBB2 IL1B KDR MTA3 SNAI1

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:



Diseases related to Gastroesophageal Junction Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:


abdominal pain

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 skeleton MP:0005390 8.92 ERBB2 IL1B KDR SNAI1

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Herceptin 17 46 TRASTUZUMAB Genentech Approved October 1998

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
2
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
3
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
4
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
5 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
8 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
9 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
13
Levoleucovorin Approved Phase 3,Phase 1,Phase 2 68538-85-2
14
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
15
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
16
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
17
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
18
Cetuximab Approved Phase 3,Phase 2 205923-56-4 56842117 2333
19
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
20
Epirubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
21 Tegafur Approved Phase 3,Phase 2,Phase 1 17902-23-7
22
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
24
Ondansetron Approved Phase 3 99614-02-5 4595
25
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
26
Pertuzumab Approved Phase 2, Phase 3 145040-37-5, 380610-27-5 2540
27
Menthol Approved Phase 3 2216-51-5 16666
28
Vinblastine Approved Phase 2, Phase 3 865-21-4 13342 241903
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
31
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
32
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3, Phase 1 231277-92-2, 388082-78-8 208908 9941095
33 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 taxane Phase 3,Phase 2
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antibodies Phase 3,Phase 2,Phase 1
38 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
39 Immunoglobulins Phase 3,Phase 2,Phase 1
40 Antidotes Phase 3,Phase 2,Phase 1
41 Micronutrients Phase 3,Phase 2,Phase 1
42 Protective Agents Phase 3,Phase 2,Phase 1
43 Trace Elements Phase 3,Phase 2,Phase 1
44 Vitamin B Complex Phase 3,Phase 2,Phase 1
45 Vitamins Phase 3,Phase 2,Phase 1
46 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
47 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
48 Calcium, Dietary Phase 3,Phase 2,Phase 1
49 Analgesics Phase 3,Phase 1
50 Antiemetics Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 282)
id Name Status NCT ID Phase
1 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4
2 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Recruiting NCT02426034 Phase 4
3 A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4
4 Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction Unknown status NCT01697917 Phase 3
5 Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Unknown status NCT01015339 Phase 3
6 Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction Unknown status NCT01468389 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3
8 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3
9 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3
10 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3
11 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
12 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3
13 Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma Completed NCT02445209 Phase 3
14 A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer Completed NCT01662869 Phase 3
15 Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE- Recruiting NCT03019588 Phase 3
16 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
17 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Recruiting NCT01962246 Phase 2, Phase 3
18 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3
19 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Recruiting NCT01786278 Phase 2, Phase 3
20 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3
21 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Diffuse Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3
22 Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Recruiting NCT02381847 Phase 3
23 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer Recruiting NCT01917552 Phase 3
24 A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer Recruiting NCT02409199 Phase 2, Phase 3
25 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3
26 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Recruiting NCT02158988 Phase 3
27 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Recruiting NCT02564263 Phase 3
28 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Recruiting NCT00450203 Phase 2, Phase 3
29 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Recruiting NCT02625610 Phase 3
30 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3
31 FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Recruiting NCT02581462 Phase 2, Phase 3
32 Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Recruiting NCT02578368 Phase 3
33 Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3
34 Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Recruiting NCT01404156 Phase 2, Phase 3
35 Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma Recruiting NCT01924819 Phase 2, Phase 3
36 FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Recruiting NCT02661971 Phase 2, Phase 3
37 Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer Recruiting NCT02537171 Phase 3
38 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
39 PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA Recruiting NCT03006432 Phase 3
40 Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer Recruiting NCT03042611 Phase 3
41 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Active, not recruiting NCT02370498 Phase 3
42 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting NCT02545504 Phase 3
43 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Active, not recruiting NCT02625623 Phase 3
44 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting NCT02314117 Phase 3
45 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Active, not recruiting NCT02494583 Phase 3
46 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Active, not recruiting NCT02178956 Phase 3
47 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Active, not recruiting NCT00680901 Phase 3
48 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3
49 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Active, not recruiting NCT01170663 Phase 3
50 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Active, not recruiting NCT03013010 Phase 3

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

39
Breast, Lymph Node, Testes, Liver, Brain

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 59)
id Title Authors Year
1
Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. ( 27198655 )
2016
2
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. ( 26747859 )
2016
3
Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. ( 27065846 )
2016
4
No Survival Difference with Neaodjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. ( 27641320 )
2016
5
Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. ( 27635275 )
2016
6
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. ( 27774774 )
2016
7
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( 26354521 )
2015
8
Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. ( 26625793 )
2015
9
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. ( 25753188 )
2015
10
Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. ( 26683954 )
2015
11
Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. ( 25159681 )
2014
12
Combined neutron brachytherapy with external beam radiation in patients with inoperable gastroesophageal junction adenocarcinoma. ( 25296599 )
2014
13
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. ( 24774780 )
2014
14
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. ( 23656792 )
2013
15
Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. ( 24236193 )
2013
16
Reconstructive options for gastroesophageal junction adenocarcinoma after Roux-en-Y gastric bypass. ( 23988286 )
2013
17
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( 23921575 )
2013
18
Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma. ( 24356933 )
2013
19
Meningeal carcinomatosis: a metastasis from gastroesophageal junction adenocarcinoma. ( 24454393 )
2013
20
Results of docetaxel plus oxaliplatin (DOCOX) A+ cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. ( 23747051 )
2013
21
The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. ( 23671646 )
2013
22
Unanswered questions in the management of gastroesophageal junction adenocarcinoma. ( 23714486 )
2013
23
Distant lymph node metastases in gastroesophageal junction adenocarcinoma: impact of endoscopic ultrasound-guided fine-needle aspiration. ( 24949383 )
2013
24
Gastroesophageal junction adenocarcinoma metastasizing to gingiva. ( 23776844 )
2013
25
The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. ( 23420289 )
2013
26
Relationship between gastroesophageal junction adenocarcinoma and Helicobacter pylori infection in Japan. ( 22472851 )
2012
27
Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. ( 23412351 )
2012
28
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. ( 22646280 )
2012
29
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. ( 21769462 )
2012
30
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. ( 21617522 )
2012
31
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study. ( 21063792 )
2011
32
Gastroesophageal junction adenocarcinoma of young patients who underwent curative surgery: a comparative analysis with older group. ( 21264755 )
2011
33
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. ( 20574790 )
2011
34
Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma. ( 21338186 )
2010
35
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. ( 20458043 )
2010
36
Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma. ( 19443416 )
2009
37
Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. ( 19267943 )
2009
38
Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma. ( 19139425 )
2009
39
Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. ( 19487968 )
2009
40
Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma? ( 19343142 )
2008
41
Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels. ( 18438866 )
2008
42
Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. ( 17662776 )
2007
43
Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. ( 17265786 )
2007
44
New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother? ( 17327615 )
2007
45
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. ( 17667920 )
2007
46
High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. ( 18000363 )
2007
47
The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with gastroesophageal junction adenocarcinoma in Japan. ( 17450443 )
2007
48
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). ( 17164226 )
2007
49
Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status. ( 16573782 )
2006
50
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. ( 17114652 )
2006

Variations for Gastroesophageal Junction Adenocarcinoma

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 ERBB2 IL1B KDR SNAI1
2 11.56 ERBB2 KDR
3 11.51 IL1B KDR
4 11.45 KDR SNAI1
5
Show member pathways
11.35 ERBB2 IL1B
6
Show member pathways
11.22 ERBB2 IL1B KDR
7 11.01 ERBB2 SNAI1

GO Terms for Gastroesophageal Junction Adenocarcinoma

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.26 ERBB2 KDR
2 positive regulation of angiogenesis GO:0045766 9.16 IL1B KDR
3 signal transduction by protein phosphorylation GO:0023014 8.96 ERBB2 KDR
4 positive regulation of protein phosphorylation GO:0001934 8.8 ERBB2 IL1B KDR

Molecular functions related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.16 ERBB2 KDR
2 growth factor binding GO:0019838 8.96 ERBB2 KDR
3 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.62 ERBB2 KDR

Sources for Gastroesophageal Junction Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....